FILING ANALYSIS · WEDNESDAY, JUNE 24
Circio Holding Asa 0RIS — RNS
positive
Circio Holding ASA announces a research collaboration with Tcelltech to develop next-generation in vivo CAR-T and TCR-T cell therapies using Circio's circVec technology and Tcelltech's nanoSMAR vector platform, aiming for safer and more durable engineered T-cell therapies. This partnership is part of Circio's strategy to test circVec across multiple modalities and delivery technologies.
The filing
Circio Holding Asa — Circio And Tcelltech Jointly Announce Car T C
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →